The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques

Mireille Laforge, …, Anna Senik, Jérôme Estaquier

*J Clin Invest.* 2018;128(4):1627-1640. [https://doi.org/10.1172/JCI95127](https://doi.org/10.1172/JCI95127).

AIDS/HIV Immunology

Apoptosis has been proposed as a key mechanism responsible for CD4$^+$ T cell depletion and immune dysfunction during HIV infection. We demonstrated that Q-VD-OPH, a caspase inhibitor, inhibits spontaneous and activation-induced death of T cells from SIV-infected rhesus macaques (RMs). When administered during the acute phase of infection, Q-VD-OPH was associated with (a) reduced levels of T cell death, (b) preservation of CD4$^+$/CD8$^+$ T cell ratio in lymphoid organs and in the gut, (c) maintenance of memory CD4$^+$ T cells, and (d) increased specific CD4$^+$ T cell response associated with the expression of cytotoxic molecules. Although therapy was limited to the acute phase of infection, Q-VD-OPH–treated RMs showed lower levels of both viral load and cell-associated SIV DNA as compared with control SIV-infected RMs throughout the chronic phase of infection, and prevented the development of AIDS. Overall, our data demonstrate that Q-VD-OPH injection in SIV-infected RMs may represent an adjunctive therapeutic agent to control HIV infection and delaying disease progression to AIDS.

Find the latest version:

http://jci.me/95127/pdf
The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques

Mireille Laforge,1 Ricardo Silvestre,1,2,3 Vasco Rodrigues,1,4,5 Julie Caribal,1 Laure Campillo-Gimenez,1 Shahul Mouhamad,1 Valérie Monecaux,6 Marie-Christine Cumont,6 Henintsoa Rabezanahary,9 Alain Pruvost,6 Anabela Cordeiro-da-Silva,4,5 Bruno Hurtrel,6 Guido Silvestri,6 Anna Senik,1 and Jérôme Estaquier1,7

1-CNRS FR 3636, Université Paris Descartes, Paris, France. 2-Microbiology and Infection Research Domain, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal. 3-ICVS/3BS – PT Government Associate Laboratory, Braga/Guimarães, Portugal. 4-IBS – Instituto de Investigação e Inovação em Saúde and Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal. 5-Unité de Physiopathologie des Infections Lentivirales, Institut Pasteur, Paris, France. 6-Université Laval, Centre de Recherche du CHU de Québec, Quebec City, Quebec, Canada. 7-CEA, iBiTecS, SPI, Laboratoire d’Etude du Métabolisme des Médicaments, Gif-sur-Yvette, France. 8-Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.

Apoptosis has been proposed as a key mechanism responsible for CD4+ T cell depletion and immune dysfunction during HIV infection. We demonstrated that Q-VD-OPH, a caspase inhibitor, inhibits spontaneous and activation-induced death of T cells from SIV-infected rhesus macaques (RMs). When administered during the acute phase of infection, Q-VD-OPH was associated with (a) reduced levels of T cell death, (b) preservation of CD4+/CD8+ T cell ratio in lymphoid organs and in the gut, (c) maintenance of memory CD4+ T cells, and (d) increased specific CD4+ T cell response associated with the expression of cytotoxic molecules. Although therapy was limited to the acute phase of infection, Q-VD-OPH-treated RMs showed lower levels of both viral load and cell-associated SIV DNA as compared with control SIV-infected RMs throughout the chronic phase of infection, and prevented the development of AIDS. Overall, our data demonstrate that Q-VD-OPH injection in SIV-infected RMs may represent an adjunctive therapeutic agent to control HIV infection and delaying disease progression to AIDS.

Introduction

Pathogenic HIV and SIV infections of humans and rhesus macaques (RMs), respectively, are associated with progressive CD4+ T cell depletion and having a short half-life (1, 2). The regulation of T lymphocyte numbers that occurs physiologically during any normal immune response (i.e., the contraction phase) is accomplished by the concerted action of two fundamental biological mechanisms, known as activation-induced cell death (AICD) and death by neglect or cytokine deprivation. AICD, which acts to limit the accumulation of T cells that have responded to a certain antigen, is dependent on the death receptor CD95/Fas and associated with the activation of cysteine proteases (caspases) leading to apoptosis. As antigen levels decrease, growth factors and cytokines also become scarce, activating the proapoptotic Bcl-2 family member Bim, which engages the mitochondrial pathway of apoptosis (3–5). The cooperative interplay between these two mechanisms of cell death ensures the elimination of most effector T cells as the system returns to the steady state, while allowing the survival of a small pool of long-living, self-sustaining memory T cells.

Studies conducted in both pathogenic and nonpathogenic models of SIV infection have demonstrated a direct correlation between progression to AIDS and the levels of CD4+ T cell apoptosis early after infection (6–17). In the context of HIV/SIV infections, the increased level of apoptosis can be related to the presence of heightened levels of immune activation (18–20). CD4+ T cells from HIV-infected individuals and SIV-infected RMs are highly sensitive to Fas-mediated apoptosis (9, 14, 21–24), which is prevented by caspase inhibitors such as Z-VAD-FMK (10, 14, 21, 25–27). However, Z-VAD-FMK interferes with cell proliferation (28, 29), thus limiting its potential for clinical use. Furthermore, we and others have also shown that the proapoptotic proteins Bim and Bak are upregulated in CD4+ T cells from chronically HIV-infected individuals and in SIV-infected RMs compared with healthy donors (14, 30). However, spontaneous T cell death was prevented only to a limited extent by Z-VAD-FMK but prevented by cytokines (9, 14, 21, 31, 32).

In addition to viral replication (33–39), in which lysosome destabilization is of crucial importance (40), cell death of CD4+ T cells can be mediated by viral particles, often defective, that can still bind to — and enter into — CD4+ T cells; viral particles thus represent potential candidates for the killing of CD4+ T cells in the absence of productive infection (11, 23, 24, 41–50). Therefore, the HIV-1 envelope protein induces the activation of caspase-3 and caspase-8 (47, 51). Whereas Z-VAD-FMK poorly inhibits spontaneous cell death (14), other groups have proposed that quiescent CD4+ T cells die by caspase-1-mediated cell death triggered by abortive viral infections, which initiate inflammatory reactions (52), or even by autophagy (53). Thus, several proteases have been proposed to regulate the death of primary CD4+ T cells in the context of HIV/SIV infections, and these could serve as therapeutic targets. Until now, very few interventions have been tested in vivo to prevent CD4+ T cells death in the context of HIV/SIV infections.

In this study, we found that Q-VD-OPH, a broad caspase inhibitor, reduces spontaneous and Fas-mediated apoptosis in
cells recovered from the lymphoid organs of SIVmac251-infected RMs. Furthermore, we demonstrated that in vivo administration of Q-VD-OPH during the acute phase of SIV infection reduced the levels of memory CD4+ T cell apoptosis, while maintaining the CD4+/CD8+ T cell ratio and preserving the pool of memory CD4+ T cells, leading to activation of specific effector CD4+ T cells and expression of cytotoxic molecules. Most importantly, Q-VD-OPH-treated RMs exhibited reduced viral load and delayed progression to AIDS.

Results

Q-VD-OPH inhibits in vitro spontaneous and activation-mediated T cell death. Several proteases (including cysteines, serine, and calpain proteases) have been proposed as regulating the death of primary CD4+ T cells in the context of HIV/SIV infections. Given the lower impact of Z-VAD-FMK on spontaneous cell death, we assessed the effectiveness of different compounds in preventing cell death either spontaneously or after incubation with Fas ligand (FasL). Several synthetic protease inhibitors, including an inhibitor of autophagy (3-MA), cathepsin inhibitors (Z-FG-NHO2-BzME), calpain inhibitors (ALLN, Z-FA-CHO, calpeptin, and calpastatin), serine protease inhibitors (AEBSF, aprotinin, Elastinal, and TLCK), cysteine protease inhibitors (E-64 and leupeptin), aspartic protease inhibitor (pepstatin A), metalloprotease inhibitors (1, 10-phenanthroline), and a broad caspase inhibitor (Q-VD-OPH) were tested ex vivo using T cells isolated from chronically SIV-infected RMs. Our results showed that Q-VD-OPH inhibits spontaneous cell death of CD4+ T cells isolated from peripheral lymph nodes (LNs) (axillary and inguinal) and spleen of SIV-infected RMs (axillary, 24.9% ± 3.33% versus 15.4% ± 4.59%, P = 0.019; inguinal, 21.7% ± 5.6% versus 13.5% ± 4.52%, P = 0.006; spleen, 33.1% ± 4.9% versus 20.2% ± 3.92%, P = 0.012, for control and Q-VD-OPH–treated cells, respectively) (Figure 1A). The effect was not restricted to CD4+ T cells, since death of CD8+ T cells of SIV-infected RMs was similarly inhibited (axillary, 41% ± 6% versus 20.7% ± 1.6%, P = 0.017; inguinal, 39.9% ± 3.9% versus 23.1% ± 2.9%, P = 0.007; spleen, 44.7% ± 4.4% versus 23.1% ± 2.27%, P = 0.0009, for control and Q-VD-OPH–treated cells, respectively), and reached the levels observed for CD8+ T cells isolated from healthy RMs (Figure 1B). The other compounds tested had no preventive effect (data not shown).

Because we have previously observed that Z-VD-FMK was only partly effective in blocking spontaneous T cell death (14), in a cell-free system, using recombinant effector caspases as targets, we compared the two inhibitors. We demonstrated that Q-VD-OPH was more effective than Z-VD-FMK in blocking caspase-3– and caspase-7–mediated poly(ADP-ribose) polymerase (PARP) activities. Q-VD-OPH was more effective than Z-VAD-FMK in blocking caspase-3– and caspase-7–mediated poly(ADP-ribose) polymerase (PARP) activities. Q-VD-OPH was more effective than Z-VAD-FMK in blocking caspase-3– and caspase-7–mediated poly(ADP-ribose) polymerase (PARP) activities.
We then decided to analyze in detail the effect of Q-VD-OPH on T cell subsets. Immunophenotypical analysis conducted in fresh cells recovered from chronically SIV-infected RMs revealed that the preventive effect of Q-VD-OPH occurred mainly within the effector memory CD4+ T cell population (Tem, CD45RA–CD62L–) (26.1% ± 3.6% and 9.5% ± 2.2% for control and Q-VD-OPH–treated cells, respectively) and to a lesser extent within cleavage, which is a prototypical substrate of effector caspases (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI95127DS1). Furthermore, Q-VD-OPH could also inhibit caspase-1 activity more efficiently than Z-VAD-FMK (Supplemental Figure 1B). These results demonstrated the superior efficacy of Q-VD-OPH in blocking caspase activation as compared with Z-VAD-FMK. We then decided to analyze in detail the effect of Q-VD-OPH on T cell subsets. Immunophenotypical analysis conducted in fresh cells recovered from chronically SIV-infected RMs revealed that the preventive effect of Q-VD-OPH occurred mainly within the effector memory CD4+ T cell population (Tem, CD45RA–CD62L–) (26.1% ± 3.6% and 9.5% ± 2.2% for control and Q-VD-OPH–treated cells, respectively) and to a lesser extent within
terminally differentiated CD4+ T cells (CD45RA+CD62L-, 9.5% ± 2.2% and 4.5% ± 1.5%) (Figure 1C). In addition, Q-VD-OPH protected CD4+ and CD8+ T cells from (a) FasL-mediated cell death (Figure 1, D and E) and (b) AICD, which depends on the Fas/FasL pathway (Figure 1F). None of the other inhibitors that we tested afforded similar protection (data not shown). As a consequence of its antiapoptotic effect, the presence of Q-VD-OPH was associated with an increased proportion of proliferating T cells (CFSE dilution assay) after stimulation with concanavalin A (ConA) (Supplemental Figure 2).

Overall, these results demonstrated that Q-VD-OPH prevents ex vivo spontaneous and Fas-mediated T cell death and enhances proliferation of cells isolated from chronically SIV-infected RMs.

In vivo administration of Q-VD-OPH prevents T cell death in SIV-infected RMs. To investigate the effect of Q-VD-OPH in vivo, we initially performed pharmacokinetic studies in uninfected animals. Q-VD-OPH was administered at 20 and 40 mg/kg. These doses were chosen based on in vivo experiments performed in murine models (54, 55). The concentration of Q-VD-OPH was measured in the sera sampled at different time points after injection and in LNs recovered upon 4 hours of treatment. As expected, we found the higher concentrations of the compound, both in sera and LNs, and highest half-life in animals treated with the higher dose (Supplemental Figure 3, A and B). Moreover, we analyzed the levels of urea, transaminase (alanine aminotransferase [ALAT] and aspartate aminotransferase [ASAT]), and creatinine to assess liver and renal toxicity. No significant differences were found in any of the toxicity parameters evaluated between the sera of animals administered 20 mg/kg Q-VD-OPH and those receiving vehicle alone (Supplemental Figure 3C). Among the animals treated with 40 mg/kg only 1 RM (no. 9052) showed higher levels of urea, ALAT, and creatinine compared with the placebo-treated (DMSO) RMs (Supplemental Figure 3C). Thus, we selected the dose of 20 mg/kg for the in vivo experiments included in this study.

In vivo administration of Q-VD-OPH prevents T cell death in SIV-infected RMs. To investigate the effect of Q-VD-OPH in vivo, we initially performed pharmacokinetic studies in uninfected animals. Q-VD-OPH was administered at 20 and 40 mg/kg. These doses were chosen based on in vivo experiments performed in murine models (54, 55). The concentration of Q-VD-OPH was measured in the sera sampled at different time points after injection and in LNs recovered upon 4 hours of treatment. As expected, we found the higher concentrations of the compound, both in sera and LNs, and highest half-life in animals treated with the higher dose (Supplemental Figure 3, A and B). Moreover, we analyzed the levels of urea, transaminase (alanine aminotransferase [ALAT] and aspartate aminotransferase [ASAT]), and creatinine to assess liver and renal toxicity. No significant differences were found in any of the toxicity parameters evaluated between the sera of animals administered 20 mg/kg Q-VD-OPH and those receiving vehicle alone (Supplemental Figure 3C). Among the animals treated with 40 mg/kg only 1 RM (no. 9052) showed higher levels of urea, ALAT, and creatinine compared with the placebo-treated (DMSO) RMs (Supplemental Figure 3C). Thus, we selected the dose of 20 mg/kg for the in vivo experiments included in this study.

Six RMs of Chinese origin were treated during the acute phase of SIVmac251 infection by intravenous injection of Q-VD-OPH (20 mg/kg), whereas vehicle was injected in the second group of RMs as a control (Supplemental Figure 4). The dosing regimen consisted of 5 Q-VD-OPH injections on days 5, 7, 9, 11, and 14 after infection, thus covering the peak of T cell apoptosis observed during acute SIV infection (13–17). No statistically significant difference was observed in red blood cell and platelet counts or hemoglobin concentration between treated and untreated RMs, ruling out possible side effects of Q-VD-OPH injection during infection (Supplemental Figure 5). To monitor the in vivo levels of T cell death, we collected peripheral axillary and inguinal LNs from SIV-infected RMs on days 7, 11, 14, 18.
and 60 after infection. Indeed, the levels of apoptosis in peripheral LNs of RM are predictive of progression to AIDS (13, 15, 16). We first quantified the number of dying cells in vivo in LNs using a TUNEL assay as previously described (13, 16). We observed that the levels of 'TUNEL' cells were significantly lower in SIV-infected RMs treated with Q-VD-OPH as compared with untreated animals (Supplemental Figure 6, A and B). We then measured, in the sera of treated and control RMs, the levels of IL-18, a proinflammatory cytokine belonging to the IL-1 superfamily whose maturation is dependent on caspase activation (56, 57) and that was previously reported to be increased during the acute phase of SIV infection in RMs (58, 59). We found that in Q-VD-OPH-treated RMs, IL-18 levels were significantly decreased on postinfection (p.i.) days 11 and 14 compared with those in control SIV-infected RMs (Supplemental Figure 7A), thus suggesting in vivo inhibition of caspase activation.

We then quantified ex vivo the levels of spontaneous and FasL-mediated apoptosis of CD4+ T cells isolated from LNs. Our data demonstrated lower levels of CD4+ T cell death from LNs isolated from RMs treated with Q-VD-OPH compared with untreated RMs. This protective effect was observed on days 7, 11, and 14 after infection (Figure 2, A and C). Of note, however, the level of CD4+ T cell death remained significantly lower in Q-VD-OPH–treated RMs as compared with controls on day 60 after infection, i.e., more than 6 weeks after the interruption of treatment. This long-term effect of Q-VD-OPH administration was confirmed by the observation of lower levels of CD4+ T cell death in the peripheral blood up to 1 year after treatment (Figure 2, A–C) and higher CD4/CD8 ratios in peripheral blood throughout infection (Figure 3, A–C) as compared with control animals. On the sacrifice day, we found that the CD4/CD8 ratio in spleen and axillary, inguinal, and mesenteric LNs were also higher in Q-VD-OPH–treated RMs as compared with the placebo group (Figure 3E) despite a longer duration of SIV. Since high expression of β7 on CD4+ T cells in peripheral blood is a useful surrogate for estimating intestinal CD4+ T cell loss (64), we also assessed during the acute phase the dynamics of CD4+ T cells coexpressing

**Figure 4. Q-VD-OPH prevents the depletion of β7hi CD4+ T cells in SIV-infected RMs.** (A) Representative flow cytometric analyses of coexpression of CD45RA and β7hi integrin expression on CD3+CD4+ T cells from peripheral blood of healthy RMs (day 0) and of either untreated (placebo) or Q-VD-OPH–treated RMs (Q-VD) on day 14. (B) Percentages of CD3+CD4+CD45RA β7hi T cell subset of placebo- (n = 8) and Q-VD-OPH–treated RMs (n = 6) at different time points after infection. (C) sCD14 was measured in the sera by ELISA at different time points p.i. Statistical differences were assessed using the Mann-Whitney U test (*0.01 < P < 0.05; **0.001 < P < 0.01; ***P < 0.001). Prism was used to present the results in box-and-whisker plots showing the minimum and maximum of all the data.
CD45RA and β7th. Our results showed the early loss of the circulating β7th CD4+ T cell population in SIV-infected RMs. In contrast, such loss was not observed in Q-VD-OPH-treated RMs (Figure 4, A and B). Furthermore, we measured the levels of soluble CD14 (sCD14), which is a well-established marker of microbial translocation associated with the depletion of CD4+ T cells in the intestine and with clinical end points (65–69). We found that sCD14 was significantly decreased in Q-VD-OPH-treated SIV-infected RMs as compared with control animals (Figure 4C).

Because CD4+/CD8+ T cell ratio is considered a strong marker of disease progression to AIDS (70), our results demonstrated that treatment with Q-VD-OPH afforded long-term protection preserving CD4+ T cell homeostasis.

Q-VD-OPH treatment prevents the loss of memory T cells and decreases immune activation. To better understand the repopulation of CD4+ T cells, and because the progressive loss of central and effector memory CD4+ T cells is associated with AIDS pathogenesis (13, 15, 71–76), we next investigated, in our cohort of SIV-infected RMs, the effect of Q-VD-OPH on the dynamics of CD4+ T cell subsets. We found that CD4+ Tem (CD45RA CD62L) cells from LN of Q-VD-OPH-treated SIV-infected RMs were less prone to die as compared with LN-derived CD4+ Tem cells of nontreated SIV-infected RMs during the acute phase of infection and up to 60 days after termination of the treatment (Figure 5A). A similar pattern of reduced spontaneous cell death, although to a lesser extent, was observed in both central memory (Tcm, CD45RA CD62L) and terminally differentiated (CD45RA-CD62L) CD4+ T cells (Figure 5A). Although the death of naive CD4+ T cells was low, we observed a slight increase in naive CD4+ T cells from LNs of Q-VD-OPH-treated SIV-infected RMs. Consistent with this protective effect of Q-VD-OPH, the percentage of Tem cells among the total LN T cell pool was greater in treated SIV-infected RMs as compared with control animals (Figure 5A). Of note, CD4+ Tcm cells, which are also progressively depleted during pathogenic SIV infection, were similarly preserved in Q-VD-OPH-treated RMs as compared with controls (Figure 6A). The distribution of the different T cell subsets among the pool of CD4+ T cells (Figure 6C) illustrates the selective preservation of specific CD4+ Tcm cell subsets in Q-VD-OPH-treated RMs.

Furthermore, Q-VD-OPH treatment was associated with a transient decrease in CD8+ Tem and Tcm cell death in LNs of SIV-infected RMs (Figure 5B) and a slight increase in levels of naive CD8+ T cells on day 11. As a consequence, Q-VD-OPH-treated RMs showed a higher percentage of LN-based CD8+ Tcm cells as compared with control animals, which exhibited, as expected, higher percentages of LN-based CD8+ Tem and terminally differentiated T cells (Figure 5B). As shown in Figure 6, B and D, the distribution kinetics of the distinct CD8+ T cell subsets clearly illustrates the differences in the balance of terminally differentiated T cells and Tcm cells in Q-VD-OPH-treated and untreated RMs. We then assessed the levels of immune activation of LN CD8+ T cells and found that Q-VD-OPH treatment was associated with decreased levels of CD8+ T cell activation, as measured by the frequency of CD8+ T cells expressing the activation markers HLA-DR and Ki-67, as compared with untreated controls (Supplemental Figure 10).

Together, these results suggest that Q-VD-OPH treatment improved the overall homeostasis of memory T cells and reduced the level of immune activation during the chronic phase of SIV infection.

Q-VD-OPH treatment induces SIV-specific CD4+ T effector cells. To investigate the impact of Q-VD-OPH on SIV-specific CD4+ T cell immune response, we next evaluated the expression of IFN-γ and TNF-α by intracellular cytokine staining (ICS) after in vitro HIV-2 antigen stimulation (Supplemental Figure 10). The use of such crude antigen preparation, as opposed to individual peptides, has been validated in our laboratory as well as others as a tool to best detect SIV-specific CD4+ T cell responses in the setting of the broad MHC genetic polymorphisms present in RMs (13, 77, 78). We found that at 2 weeks after infection, the percentage of SIV-specific CD4+ T cells expressing IFN-γ and TNF-α was approx-
approximately 10-fold higher in Q-VD-OPH–treated than control RMs (Supplemental Figure 11A). In vitro T cell proliferation, as measured by thymidine incorporation after 5 days of culture, confirmed the increased ability of CD4+ T cells from Q-VD-OPH-treated SIV-infected RMs to respond to HIV-2 antigens as compared with those isolated from control animals (Supplemental Figure 11B).

To determine the effect of Q-VD-OPH on the expression of cytotoxic molecules, we next analyzed the expression of perforin, granzyme B, and granulysin in purified T cells by Western blotting (Supplemental Figure 12). Purified CD8+ T cells from untreated SIV-infected RMs showed reduced expression of perforin and granulysin molecules as compared with those from healthy animals, with no full restoration in Q-VD-OPH-treated SIV-infected RMs (Supplemental Figure 12A). In 1 SIV-infected RM (lane 4), a higher level of granzyme B was found to be associated with the lowest level of perforin, which is essential for granzyme B–mediated killing. A growing body of evidence suggests that CD4+ T cells also can themselves display potent antiviral activity by killing virus-infected cells including cytomegalovirus (79), influenza (80), Friend virus (81), Epstein-Barr virus (82), murine poxvirus (83), and BK polyomavirus (84). In HIV-infected individuals, the presence of cytolytic HIV-specific CD4+ T cells has been associated with control of virus replication and delayed disease progression (85–89). Interestingly we observed that the expression of perforin, granzyme B, and granulysin in CD4+ T cells was preserved or even augmented in chronically Q-VD-OPH–treated SIV-infected RMs compared with untreated SIV-infected RMs (Supplemental Figure 12B). We then assessed the proportion of cytotoxic CD4+ T cells by analyzing the expression of perforin, granzyme B, and granulysin by flow cytometry. Our results demonstrated that CD4+ T cells from Q-VD-OPH–treated SIV-infected RMs expressed higher levels of perforin, granzyme B, and granulysin than those from naive RMs (Figure 7, A and B). Similarly, the frequency and the numbers of CD4+ T cells expressing TIA1, the cytotoxic granule-associated protein, are preserved under treatment compared with control animals in chronically Q-VD-OPH–treated SIV-infected RMs (Figure 7, C and D).

Together, these findings indicated that treatment with Q-VD-OPH resulted in more robust SIV-specific CD4+ T cell responses, associated with higher levels of total cytotoxic CD4+ T cells.

Q-VD-OPH reduces viral replication and delays progression to AIDS. The observations that Q-VD-OPH treatment of SIV-infected RMs improves the overall homeostasis of CD4+ T cells prompted us to investigate the impact of Q-VD-OPH treatment on the levels of SIV replication. We found that the levels of viral replication were significantly lower in SIV-infected Q-VD-OPH–treated RMs as compared with control animals (Figure...
Together, these results demonstrate that treatment with Q-VD-OPH during the acute phase of SIV infection in RMs resulted in long-term control of viral replication and delayed disease progression.

Discussion

In this study, we have shown that Q-VD-OPH may represent a novel compound to be explored as a potential treatment for HIV/SIV infection due to its strong anti-caspase effect in vitro and in vivo, which results in better immunological, virological, and clinical outcomes of SIV infection in RMs. We wish to point out that while many studies in vivo and in vitro have revealed a clear association between HIV/SIV disease progression and the levels of T cell death, the current study is the first to our knowledge showing, in a highly relevant animal model, that a pharmacological inhibitor of caspase has a significant impact on the pathogenicity of an AIDS virus infection.
The main results of this study are that early and transient Q-VD-OPH therapy (a) prevents the activation of caspases and the occurrence of T cell death; (b) favors the preservation of both Tcm and Tem cells, which is associated with stronger SIV-specific CD4+ T cell responses; (c) reduces CD4+ T cell depletion in the gut and immune activation; (d) reduces the levels of virus replication; and (e) delays the development of AIDS.

Recent studies suggest that early treatment initiation during primary HIV-1 infection may reduce viral replication (90), limit viral reservoirs (91), and preserve the antiviral host immune response (92, 93). Recently, the administration of a recombinant rhesus anti-α4β7 mAb, which maintains normal CD4+ T cell counts in the blood and in gut-associated lymphoid tissue (GALT) was found to control viremia without the need for further therapy (94). However, the mechanisms associated with this long-term protection remain poorly understood. Our results demonstrated that treatment with Q-VD-OPH during the acute phase of SIV infection is associated with a persistent expansion of specific memory CD4+ T cells. Because at the same time we observed lower viremia, we cannot exclude that this process participates in the reconstitution of these immune cells, whether these immune cells contribute to virologic control, or even both. Of note, our observation is consistent with the fact that depletion of CD4+ T cells prior to SIV infection of RMs is associated with loss of virus control, rapid disease progression, and neurodegenerative diseases (95). We have not analyzed in detail all lymphoid or non-lymphoid cell types reported to be abnormally primed to undergo death during HIV/SIV infection (61, 96–99), due to the relatively limited availability of samples and tissues; however, our observation that the pool of CD4+ T cells expressing β7 hi (64) is preserved during the acute phase and associated with lower levels of sCD14 in Q-VD-OPH–treated SIV-infected RMs suggests that this treatment was associated with a preserved intestinal CD4+ T cell pool and integrity of the epithelial barrier of the gastrointestinal tract (65–67). Interestingly, at the time of necropsy, the ratio of CD4 to CD8 in peripheral LNs as well as the spleen and mesenteric LNs was higher in Q-VD-OPH–treated SIV-infected RMs as compared with placebo-treated controls, thus indicating a global preservation of T cell homeostasis. In this study, we have shown for the first time to our knowledge that a strong, selective blockade of caspase activation may have a significant beneficial impact on the immunological, virological, and clinical course of SIV infection. Importantly, although Q-VD-OPH was injected only during the acute phase of infection, the beneficial effect persisted throughout the chronic phase. Interesting work published by Whitney et al. (100) demonstrates that blocking viral replication during the acute phase of infection, the beneficial effect persisted throughout the chronic phase. Interestingly work published by Whitney et al. demonstrates that blocking viral replication during the acute phase with antiretroviral therapy (ART) is not sufficient to provide protection once ART is interrupted. Thus, we speculate that a dual strategy combining ART with Q-VD-OPH would contribute to controlling viral rebound. In this sense, it has been shown that a vaccination based on the use of Ad26/MVA with TLR improves virologic control and delays viral rebound following discontinuation.
of ART in SIV-infected RMs (101). Therefore, a dual strategy aiming to target both the virus and the host immune system leading to the induction of robust HIV-specific immune responses may lead to better control and an HIV cure.

In this study, we found that the control of viral replication mediated by Q-VD-OPH is not dependent on the presence of increased numbers of Tem and activated CD8+ T cells. Our results indicated that treatment with Q-VD-OPH was associated with lower levels of CD8+ T cell activation, which represent a known predictive marker of disease progression in RMs of Chinese origin (13, 16, 17, 75, 102–104). This lower level of immune activation is consistent with lower viral load and cell-associated SIV DNA. However, CD8+ T cells remain sensitive to death during the chronic phase of infection, dissociating CD4+ and CD8+ T cell responses. We and others have shown that non-pathogenic models of lentiviral infections displayed some CD8+ (7, 8, 105), but not CD4+, T cell apoptosis, indicating different processes.

Our results show that Q-VD-OPH treatment during the acute phase of SIV infection is associated with higher levels of CD4+ T cells expressing cytotoxic molecules including perforin, granzyme B, and granulysin than CD4+ T cells of untreated SIV-infected or even healthy, uninfected RMs. It was previously reported that SIV-specific CD4+ T cells in SIVΔ nef-vaccinated animals express perforin and possess direct cytolytic activity (106). It has been also reported that cytotoxic CD4+ T cells are associated with early viral load set point (107). Furthermore, individuals who controlled viral replication had a significant expansion of HIV-specific CD4+ T cells compared with individuals who progressed to higher viral set points (89). Together, these studies support a role for CD4+ cytotoxic T lymphocytes (CTLs) in controlling early viral replication and contributing to delayed disease progression. The limitations of current highly active ART include the incidence of drug resistance observed in patients, issues of drug adherence, and newly acquired infections. Drug resistance represents a key aspect of treatment failure (108). Therefore, a possible beneficial effect of reinforcing the immune response and controlling the infection should be countering the emergence of resistance through the generation and recruitment of effector CD4+ T cells.

We and others have previously demonstrated that in HIV-infected individuals, caspases are activated through FasL, thus leading to apoptosis (9, 10, 21), and that the activation of caspase occurs in bystander CD4+ T cells (21, 23, 52). In particular, caspase-1 activation is associated with increased inflammation in myeloid cells (109–112). Thus, in monocytes/macrophages, which are the major source of IL-18, inflammasome activation and secretion of mature IL-18 require the activation of caspase-1 (56, 57). In this context, our finding of decreased amounts of IL-18 in Q-VD-OPH–treated RMs indicated that this compound targets caspase-1 in vivo, consistent with the in vitro data (Supplemental Figure 1B), and that Q-VD-OPH modulates inflammasome activity in monocytes/macrophages. As such, Q-VD-OPH appears to act as a potent in vivo modulator of pyroptosis (21, 23, 52). The decrease in IL-18 and FasL associated with Q-VD-OPH treatment during the acute phase of SIV infection may also have an indirect impact on the levels of CD4+ T cell apoptosis, as anti-FasL treatment during the initial stages of SIV infection has been reported to preserve T cell homeostasis and sustain cell-mediated immunity to SIV (113).

Therefore, we propose that a key immunological effect of Q-VD-OPH is the relative preservation of CD4+ memory T cell homeostasis, with increased activity of SIV-specific effector CD4+ T cells.

In conclusion, the current study provides evidence that the administration of the anti-caspase agent Q-VD-OPH, in the absence of ART, during the acute phase of SIV infection in RMs is associated with a number of beneficial effects that positively influence the immunological, virological, and clinical course of the infection. We believe that this molecule may represent a novel adjunctive immunotherapeutic approach in the context of HIV infection.

Methods

Animals and virus infection. Eighteen female RMs (Macaca mulatta) of Chinese origin, aged 4–5 years, were confirmed prior to infection as seronegative for simian T leukemia virus type 1, simian retrovirus type 1 (type D retrovirus), herpes B viruses, and SIVmac. All animals were housed in compliance with French regulations for animal care and use and were inoculated intravenously with the pathogenic SIVmac251 strain (ten 50% animal infectious doses). The pathogenic SIVmac251 isolate was provided by A.M. Aubertin (INSERM U74, Strasbourg, France) and was titrated in Chinese RMs by intravenous inoculation. RMs of Chinese origin are useful for monitoring immune dynamics, as their pathology closely mimics that in humans (17). Animals (n = 6) were treated with Q-VD-OPH (SM Biochemicals; the compound was diluted in sterile physiological water in the presence of 15% DMSO) at a dose of 20 mg/kg by the intravenous route (1 bolus was injected via the saphenous vein) on days 5, 7, 9, 11, and 14 after infection. Untreated, control animals were included, one group receiving the placebo (sterile water/DMSO) (n = 6) and a second group receiving sterile water only (n = 6). Because no difference was observed between the 2 control groups, animals were pooled. In our cohort of Chinese RMs, we assessed TRIM5α polymorphism. Seventeen of them displayed TRIM5α TFP/TFP, while only 1 RM was TRIM5α TFP/Q. Thus, Q/Q was extremely rare, consistent with previous report (114). Q-VD-OPH is a pan-caspase inhibitor (115, 116), previously reported to block caspase activity in neuronal and ischemia pathologies (55, 117). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. The animals were euthanized for ethical reasons when they showed weight loss greater than 10%, repetitive diarrhea, and declining CD4+ T cell counts.

Pharmacokinetics of Q-VD-OPH in RMs. A pharmacokinetic analysis in naive animals using 2 doses of Q-VD-OPH (20 and 40 mg/kg) was performed. Q-VD-OPH was quantified in the serum samples at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 hours and in LNs at 4 hours after intravenous injection. Protein precipitation with acetonitrile was used for sera. LNs were homogenized using a Precellys tissue homogenizer (Bertin Technologies) with a 1:2 v/v water/acetonitrile mixture. Q-VD-OPH was quantified using a Waters ACQUITY ultra-performance liquid chromatography (UPLC) system with a 2.1 × 50-mm, 1.7-m ACQUITY UPLC BEH RP18 shield column coupled to a Waters Qua9ro Premier TQ mass spectrometer operated in positive ion electrospray and multiple reaction monitoring (MRM) mode.

Determination of viral load and quantitative assessment of DNA-infected cells. RNA was extracted from the serum of SIV-infected RMs by using a Tri Reagent BD kit (Molecular Research Center Inc.). Real-time quantitative reverse transcriptase–PCR was used to determine serum viral loads. The frequency of SIV-infected cells was determined as previ-
ously reported (13) by limiting-dilution PCR of sorted CD4+ T cells from peripheral blood mononuclear cells (PBMCs), LNs, and spleen of SIV-infected rhesus. Cells were lysed with TPK buffer (10 mM Tris-HCl [pH 8.3], 50 mM KCl, 2.5 mM MgCl2, 0.5% Nonidet P-40, 0.05% Tween 20, 100 μg/ml proteinase K). After incubation for 1 hour at 56°C, proteinase K was inactivated at 95°C for 10 minutes. We subjected 20 limiting-dilution replicates to a nested PCR. SIV proviral DNA was amplified by nested PCR with SIVmac251-specific primers surrounding the nef region. After 35 cycles (95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute) with the first set of primers, Preco (5′-CAGAG-GGCTCCTCTGGACCCCTTAC) and K3 (5′-GACTGATACAGCCGAATGGTC), we amplified a fragment of 961 bp. We then reamplified 10 μl of product (30 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute) with primers K1 (5′-TGGAAGATGGATCCTCGA) and A2 (5′-GGACTAATTCTCATAGCCGCCA). The limiting-dilution PCR method detected 1 SIV DNA+ cell in 10,000 uninfected cells (CEMX174) validated with SIV-IC cells (provided by P. Villinger, University of Louisiana at Lafayette, Lafayette, Louisiana, USA), which contain a single provirus of SIVmac251 per cell.

Cell proliferation and cell death quantification. PBMCs were isolated from blood by density gradient centrifugation. Fresh cells were incubated for 24 hours at 37°C with 5% CO2 in RPMI 1640 supplemented with 10% FCS (AbCys), penicillin (50 U/ml), streptomycin (50 U/ml), glutamine (2 mM), and sodium pyruvate (1 mM). PBMCs (5 × 10^5 cells/well) were cultured in 24-well culture plates (BD Biosciences) and analyzed using FlowJo software (version 10.06).

Cells were cultured in 24-well culture plates (BD Biosciences) at a concentration of 5 × 10^6/well in the absence or presence of rhCD95L (200 ng/ml). Cell death was assessed after overnight culture by flow cytometry. Briefly, after staining with specific Abs (30 minutes at 4°C), cells were washed and then incubated with fluorescently labeled annexin V (20 minutes at 4°C). Cells were gated on FSC and SSC parameters and 20,000 events (CD3+CD4+ or CD3+CD8+ T cells) were analyzed on flow cytometer. Percentages of CD45RA+CD62L+ (naive), CD45RA+CD62L− (tem), and CD45RA−CD62L− (terminal differentiated) T cell subsets undergoing death were quantified (14, 15). Samples were acquired on a Cytomics FC 500 flow cytometer (Beckman Coulter Life Sciences) and analyzed using FlowJo software.

Lymphocyte immunophenotyping by flow cytometry. T cell immunophenotyping was performed on fresh cells by staining with the following fluorochrome-labeled monoclonal antibodies: anti-CD3 (clone SP34 and SP34+2; BD Biosciences), anti-human CD4 (clone MT477; BD Biosciences), anti-human CD8 (clone RPA-T8; BD Biosciences), anti-human CD5 (clone 2H4; Beckman Coulter), and CD26 (clone SK11; BD Biosciences). Antibodies were added to 100 μl whole blood collected in EDTA or to 2 × 10^6 LN cells. Cells were incubated for 15 minutes at room temperature. Erythrocytes were lysed with 2 ml of diluted IOTest 3 lysis solution (Beckman Coulter). The cells then were washed once in PBS buffer (1% BSA, 10 mM NaCl and resuspended in PBS containing 1% paraformaldehyde (PBS-PF) (15).

For T cell intracellular staining (75), cells were incubated in the presence of brefeldin A (5 μg/ml for the last 12 hours) before being stained with anti-CD4 and anti-CD3 mAbs (BD Biosciences), then washed twice in PBS, and further incubated with TNF-α and anti-IFN-γ (clone 4S8B3; BD Biosciences) after membrane permeabilization. Cells were examined for expression of perforin, granzyme B, granulysin, and TIA1 after cell surface staining and then fixed/permeabilized with a Cytofix/Cytoperm Kit (BD Biosciences), according to manufacturer’s instructions, and stained intracellularly for perforin (clone P344, Mabtech), granzyme B (clone GRB04, Invitrogen), granulysin (ebioDH2, eBioscience), and TIA1 (clone PNIM293, Beckman Coulter) (75). Samples were acquired on a Cytomics FC 500 flow cytometer and analyzed using FlowJo software (version 10.06).

Quantitation of FasL, IL-18, and sCD14 in sera of SIV-infected monkeys. Fasl in serum was measured using ELISA (MBL). The assay uses anti-Fasl mAbs (clones 4H9 and 4A5). The peroxidase substrate was used to quantify FasL and the optical density measured at 450 nm. Concentration was determined using a standard curve based on recombinant Fasl. IL-18 was measured by using an ELISA kit (MBL Biomedical, CliniSciences). The concentration was determined using a standard curve based on recombinant IL-18 (58). Commercial ELISA was used to measure sCD14 (R&D Systems).

Reagents. Reagents used in the study included AEBSF, aprotinin, elastatin, and TLCK (Tosyl-L-lysyl-chloromethane hydrochloride), which inhibit serine proteases, purchased from Sigma-Aldrich; E64 and leupeptin, which inhibit cysteine proteases, purchased from Sigma-Aldrich; pepstatin A, which inhibits aspartyl proteases, purchased from Sigma-Aldrich; 1,10-phenanthroline, an inhibitor of metalloproteinases, purchased from Sigma-Aldrich; N-acetyl-Leu-Leu-norleucine (ALLN), calpeptin, calpastatin, and Z-FA-CHO, which inhibit calpain proteases, purchased from Calbiochem; Z-Phe-Gly-NHO-Bz, an inhibitor of cysteine cathepsins, purchased from Calbiochem; and Q-VD-OPH, a broad caspase inhibitor, purchased from Calbiochem.

Statistics. Data are reported as mean ± SEM, and groups were compared using Mann-Whitney U test or paired Student’s t test with Prism version 6.0 (GraphPad Software). AUC was also calculated; a P value less than 0.05 was considered significant.

Study approval. All animal experiments described in the present study were conducted at the Institute Pasteur according to the European Union guidelines for the handling of laboratory animals (http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm). The numbers of animals treated with the compound were defined according to the European guidelines for nonhuman primates and the 3Rs principles (Replacement, Reduction and Refinement). The protocol was approved by the Committee on the Ethics of Animal Experiments of Île de France (PARIS 1, #200800007).

Author contributions. ML, AS, and JE conceived and designed the experiments. ML, RS, VR, JG, LCG, SM, VM, MCC, AP, and HR performed the experiments. ML, RS, VR, JG, LCG, SM, VM, MCC, AP, HR, AC, BH, GS, AS, and JE analyzed the data. ML, RS, VR, GS, and JE wrote the manuscript.

Acknowledgments. This article is dedicated to the memory of Bruno Hurtrel. We also thank Jean-Claude Ameisen for his initial support. We acknowledge Céline Gommet (Institut Pasteur) for her expertise in the follow-up of our primate cohort. We also acknowledge François Villinger, who performed TRIM5a polymorphism. ML and JG
were supported by fellowships from ANRS. RS thanks Fundação para a Ciência e a Tecnologia (FCT) for Investigator FCT Grant IF/00021/2014. This study was supported by research funding from ANRS and CIHR (MOP-133476) to JE. VR is supported by a fellowship from FCT (code SFRH/BD/64064/2009). JE thanks the Canada Research Chair program for financial assistance.

Address correspondence to: Jérôme Estaquier, Centre de Recherche du CHU de Québec, 2705, Boul. Laurier, Quebec City, Quebec GIV 4G2, Canada. Phone: 418.656.4141; Email: estaquier@yahoo.fr. Or to: Mireille Laforge, CNRS FR 3636, Université Paris Descartes, 45 rue des Saint-Pères, Paris, France. Phone: 01.42.86.41.38; Email: mireille.laforge@parisdescartes.fr.


RESERCH ARTICLE

The Journal of Clinical Investigation

1 June 2018

jci.org Volume 128 Number 4

1638


